Risedronate Sodium in Post Menopausal Osteoporosis
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The primary objective is to compare subject satisfaction of once a week dosing of 35 mg
Actonel to once daily dosing of 5 mg Actonel in postmenopausal osteoporotic women.
The secondary objectives are to measure compliance (50 % drug taken), and persistence, [and
urinary NTx (N-telopeptides) (optional)].